Close Menu

Big Biotech may not spend as much on research and development as Big Pharma, but it manages to spend a pretty penny in the pursuit of new drugs and treatments, according to Fierce Biotech’s John Carroll. And when it comes to the "biggest spenders" in biotech, the US takes the cake, boasting 11 of the top 15 largest global companies in the field. The top five are all American, Carroll adds. Amgen was the top spender in 2010, with a budget of $2.72 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.